Dr Lawrence M Garges, MD | |
1207 Evergreen Ct, Clarkston, WA 99403-2843 | |
(509) 751-0600 | |
(509) 751-8863 |
Full Name | Dr Lawrence M Garges |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Experience | 57 Years |
Location | 1207 Evergreen Ct, Clarkston, Washington |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1780677609 | NPI | - | NPPES |
1272004 | Medicaid | WA | |
805721200 | Medicaid | ID | |
030004799 | Other | RR MEDICARE |
Entity Name | Lawrence M. Garges, Md, Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1497006704 PECOS PAC ID: 6204071285 Enrollment ID: O20130321000554 |
News Archive
Scientists from the University of Sydney on Saturday have announced that they have developed a vaccine to help halt the progression of Alzheimer's disease of humans. The progress of neurodegenerative condition affects more than 35 million people worldwide.
An Ontario-led international clinical trial with 1,206 men with localized prostate cancer shows that compressing radiation treatments into four weeks from eight delivers similar outcomes.
Individual regions of the brain have to team up to get things done. And like in any team, the key to working together is communication.
Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Lawrence M Garges, MD 1207 Evergreen Ct, Clarkston, WA 99403-2843 Ph: (509) 751-0600 | Dr Lawrence M Garges, MD 1207 Evergreen Ct, Clarkston, WA 99403-2843 Ph: (509) 751-0600 |
News Archive
Scientists from the University of Sydney on Saturday have announced that they have developed a vaccine to help halt the progression of Alzheimer's disease of humans. The progress of neurodegenerative condition affects more than 35 million people worldwide.
An Ontario-led international clinical trial with 1,206 men with localized prostate cancer shows that compressing radiation treatments into four weeks from eight delivers similar outcomes.
Individual regions of the brain have to team up to get things done. And like in any team, the key to working together is communication.
Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.
› Verified 8 days ago